Papers
2
Total Citations
42
H-Index
2
About
Dr. Miles Walkden is a leading clinical researcher in urologic oncology, with a primary focus on optimizing treatment strategies for small renal masses (SRMs). His work directly addresses the critical challenge of balancing effective cancer control with the imperative to minimize overtreatment and preserve kidney function. Dr. Walkden is the principal architect of the landmark **NEST (Nephron Sparing Treatment)** feasibility study, a pioneering cohort-embedded randomized controlled trial that directly compares percutaneous cryoablation (CRA) and robot-assisted partial nephrectomy (RAPN). This work, detailed in two highly cited publications (each with 21 citations), represents a significant methodological breakthrough, overcoming the historical accrual failures that have plagued classical RCTs in this domain. By demonstrating the feasibility of a pragmatic, cohort-embedded design, Dr. Walkden has laid the essential groundwork for generating the high-level evidence desperately needed to guide clinical decision-making for the growing population of patients with incidentally detected SRMs. His contributions are pivotal in shifting the paradigm toward more tailored, nephron-sparing interventions, directly impacting patient quality of life and long-term renal health.
Research Focus
Key Achievements
Top Papers
- 1
- 2